No CrossRef data available.
Article contents
Adjunctive minocycline in clozapine and amisulpride treated schizophrenia patients with persistent symptoms
Published online by Cambridge University Press: 23 March 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective
Clozapine and amisulpride are two effective antipsychotic and their combination often is used for treatment refractory people with schizophrenia, yet many patients partially respond. Clinical data and the recent literature suggest benefits with minocycline. in our study we adjunct minocycline in five schizophrenic patients and we observed them for a period of 6 months.
Methods
Our patients received adjunct minocycline (100 mg oral capsule twice daily).
Results
Using the PANSS, we identified a statistically significant (P < 0.05) clinical improvement from the fourth week of treatment for positive mainly, and less for negative symptoms in all our patients. Global cognitive function did not differ, although there was a significant improvement in working memory favoring minocycline. Moreover there was a marked reduction of anxiety and depressive symptoms.
Minocycline was well tolerated and no patient presented side effects.
Conclusion
Minocycline seems to help significantly schizophrenic patients who do not respond fully to their medication consisted of clozapine and amisulpride. Larger studies are needed to validate these findings.
Disclosure of interest
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster Viewing: Schizophrenia and other psychotic disorders
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s842
- Copyright
- Copyright © European Psychiatric Association 2017
You have
Access
Comments
No Comments have been published for this article.